Lower Costs, Fewer Options? How Medicare Overhaul Is Shifting MS Drug Coverage

Lower Costs, Fewer Options? How Medicare Overhaul Is Shifting MS Drug Coverage

The Inflation Reduction Act (IRA) is already reshaping Medicare drug coverage for multiple sclerosis (MS), but new research in JAMA Health Forum finds this shift may come with tradeoffs for patient access. Prior to 2025, many Medicare Part D plans covered brand-name MS drugs even when generics were available, likely reflecting the influence of large manufacturer rebates and skewed incentives under Part D. However, after implementation of the IRA,